Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0596978 (Leukemia)
 15,069 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Immunofluorescent staining of peripheral blood mononuclear cells with the monoclonal antibody anti-HC2 combined with phase microscopic examination identified leukemic hairy cells in nine of 13 patients (69%) evaluated at Memorial Hospital prior to treatment with recombinant alpha-interferon (rIFN-alpha A). The remaining four patients required further studies of bone marrow or peripheral blood cytospin samples for diagnosis. In some cases a low percentage of cells staining with anti-HC2 could be significantly increased by depleting T cells from the sample using sheep red blood cell rosetting. These 13 patients represent a subgroup of patients treated on a phase II rIFN-alpha A study at Memorial Hospital. Ten patients (77%) achieved a partial response in a median of 128 days (range, 64-234). One patient achieved a minor response and two patients failed treatment. Nonhematologic toxicity, consisting of fever and malaise, was transient in all patients. Serial determinations of HC2-positive cells in the peripheral blood closely paralleled disease activity in the bone marrow in one patient treated for 4 years with various therapeutic modalities. The antibody anti-HC2 may play a significant role in the diagnosis and monitoring of hairy cell leukemia using peripheral blood sampling.
Leukemia 1987 Apr
PMID:Diagnosis and monitoring in patients with hairy cell leukemia using the monoclonal antibody anti-HC2. 366 50

A multi-institutional cooperative group trial was undertaken by the Cancer and Leukemia Group B (CALGB) to evaluate the efficacy of the combination of cisplatin and intravenous etoposide for the treatment of metastatic or recurrent non-small cell lung cancer (NSCLC). The doses used were those previously determined to be the maximally tolerated dose of this drug combination. Forty patients were entered into the trial, 37 of whom were eligible for evaluation. Cisplatin (35 mg/M2/day for 3 days) and etoposide (200 mg/M2/day for 3 days) were administered every 28 days for a planned 6 cycles of therapy. Sixteen of 37 evaluable patients (43%) responded to therapy. Myelosuppression was the dominant toxicity, with 89% of the patients experiencing grade 4 neutropenia, and nearly half grade 3 or 4 thrombocytopenia. Median survival was 8.5 months, with 30% of the patients alive at 1 year and 10% alive at 2 years. Malaise, fatigue, and peripheral neuropathy were the other major toxicities. The combination of etoposide at the dose of 200 mg/M2/day for 3 days and cisplatin at 35 mg/M2/day for 3 days is a highly potent combination against metastatic non-small cell carcinoma.
 ...
PMID:Etoposide (VP-16) and cisplatin at maximum tolerated dose in non-small cell lung carcinoma: a Cancer and Leukemia Group B study. 871 68